Anlotinib has been identified as facilitating the normalization of tumor vasculature, potentially through the activation of CD4+ T cells, which remodels the suppressive TME into a stimulatory one, thereby significantly curbing tumor growth and preventing systemic immunosuppression (Xu et al., 2022; Lou et al., 2024). The gene discussed is CD4; the disease is neoplasm.